» Articles » PMID: 36714005

Editorial: Microorganisms and Their Derivatives for Cancer Therapy

Overview
Date 2023 Jan 30
PMID 36714005
Authors
Affiliations
Soon will be listed here.
References
1.
Liu M, OConnor R, Trefely S, Graham K, Snyder N, Beatty G . Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. Nat Immunol. 2019; 20(3):265-275. PMC: 6380920. DOI: 10.1038/s41590-018-0292-y. View

2.
Liu Y, Feng J, Pan H, Zhang X, Zhang Y . Genetically engineered bacterium: Principles, practices, and prospects. Front Microbiol. 2022; 13:997587. PMC: 9606703. DOI: 10.3389/fmicb.2022.997587. View

3.
Dobosz P, Dzieciatkowski T . The Intriguing History of Cancer Immunotherapy. Front Immunol. 2020; 10:2965. PMC: 6928196. DOI: 10.3389/fimmu.2019.02965. View

4.
Kurtz C, Millet Y, Puurunen M, Perreault M, Charbonneau M, Isabella V . An engineered Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci Transl Med. 2019; 11(475). DOI: 10.1126/scitranslmed.aau7975. View

5.
Ma Y, Jiao Y, Yu Y, Jiang N, Hua Y, Zhang X . A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response. Viruses. 2018; 10(1). PMC: 5795451. DOI: 10.3390/v10010038. View